Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 60 and up

Ketofol vs Ketodex for preventing delirium after major cancer surgery in older adults

Official title: Neuroprotective Effects of Ketofol Versus Ketodex on Postoperative Delirium in Elderly Patients Undergoing Pelvi-abdominal Cancer Surgeries. A Randomized Double-blinded Comparative Study.

Run by Cairo University · NCT07627906 · Data updated 2026-11-12

This study tests whether ketofol or ketodex reduce postoperative delirium in patients aged 60 and older undergoing open pelvic-abdominal cancer surgery, compared with standard care.

More Postoperative Delirium (POD) trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages60 Years and up
SexAll
Enrollment180 (estimated)
SponsorCairo University
Academic / other
Locations1 site (Cairo, Cairo Governorate)
StatusRecruiting
StartedJuly 2026
Main results expectedDecember 2026
Study endsFebruary 2027
Registry record updatedJune 4, 2026
Trial IDNCT07627906 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 60 years or older, ASA II–III, planned open pelvi-abdominal cancer surgery, able to communicate verbally, with BMI under 35 kg/m2.

Probably not a fit

Patients with laparoscopic surgery, severe hepatic or renal impairment, significant cardiac or pulmonary disease, or those needing postoperative ICU support may not benefit from these interventions.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized phase 3 trial compares three approaches to prevent postoperative delirium in elderly cancer patients undergoing open pelvi-abdominal surgery. Participants are assigned to receive ketofol, ketodex, or standard care to see which strategy best reduces delirium after surgery. The study targets patients with ASA II–III who can communicate and are not undergoing laparoscopic procedures. Key safety considerations include avoiding recruitment of those with severe organ dysfunction or requiring postoperative ICU support. Conducted at Kasr Alainy Faculty of Medicine, the trial is led by Cairo University with no stated collaborators.

Why it matters

Potential benefit: If successful, the approach could lower delirium rates and improve recovery and outcomes after major cancer surgery in older adults.

How similar studies have gone: Previous work suggests ketamine, propofol, and dexmedetomidine may influence POD risk, but results vary and this specific three-arm comparison in this population is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients aged ≥ 60 years.
* ASA physical status II and III.
* Scheduled for open pelvi-abdominal cancer surgeries.
* Able to communicate verbally.
* BMI \< 35 kg/m2.

Exclusion Criteria:

* Patient's refusal to participate.
* Laparoscopic procedures.
* Severe hepatic (Liver enzymes are more than threefold) and renal impairment (Creatinine clearance is less than 30 ml/min).
* Severe cardiac disease (EF ≤ 40%, recent MI in the previous 3 months, NYHA ≥ III) and pulmonary disease (FEV1/FVC ratio \< 50% predicted and/or FEV1 \< 50% predicted)
* Patients require postoperative ICU admission with mechanical ventilation and or inotropic support.

Where it's running

  • Kasr Alainy Faculty of Medicine- Cairo University
    Cairo, Cairo Governorate, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.